Stroke Trials Registry

Ancrod
Viprinex® Arvin®

Action
Fibrinogenolytic agent. Purified fraction of pit viper venom, cleaves fibrinogen.

Status
Phase III trial (STAT) presented 2/99, published 5/00. European phase III trial terminated 3/2000. A phase III trial on a different dose regimen will begin in the summer of 2005.

Trial(s)
= Ongoing
= Completed

Ancrod Stroke Study

ASP I Ancrod (Viprinex™) for the Treatment of Acute Ischemic Stroke

ASP-II Ancrod Stroke Program II: Ancrod for the Treatment of Acute, Ischemic Stroke

Controlled trial of ancrod in ischemic stroke.

ESTAT European Stroke Treatment with Ancrod Trial

STAT Stroke Treatment with Ancrod Trial

Web Links and Publications

Fibrinogen depleting agents for acute ischaemic stroke.
Cochrane Database Syst Rev. 2000;(2):CD000091.

Ancrod in the treatment of acute ischemic stroke. A review of clinical data.
Cerebrovasc Dis 1998 Jan;8 Suppl 1:23-8

UID: 3